Train harder · Free ship $75+ · Gear up now
Login Register
amgen glp-1 obesity drug market potential

amgen glp-1 obesity drug market potential GLP-1 Analogues Market Size, Share

SKU: 23330902153

4.6
EUR23.01 EUR70.01

Pay in 4 interest-free payments of $5.75 Learn more

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Aug 23 - Aug 28

Description

Since the first GLP-1 received FDA approval for chronic weight management in 2014 (liraglutide, sold under the brand name Saxenda), 4 demand for these drugs has increased exponentially

amgen glp-1 obesity drug market potential GLP-1 Analogues Market Size, Share

Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression

amgen glp-1 obesity drug market potential GLP-1 Analogues Market Size, Share

The magnified percentage used in the false-negative analysis was 100%, determined based on a step-by-step strategy (Additional file 1: Fig S3, and Table S3)

amgen glp-1 obesity drug market potential GLP-1 Analogues Market Size, Share

doi: 10.1007/s40618-017-0706-y 14 ChahardoliR.Saboor-YaraghiA.-A.AmouzegarA.KhaliliD.VakiliA

amgen glp-1 obesity drug market potential GLP-1 Analogues Market Size, Share
Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy

You may also like

recommand products